Two Novel CAR-Ts for Solid Tumors Demonstrate Promising Efficacy / Activity; Are CAR-Ts More Advantageous Than Bispecific Antibodies? ESMO 2021 Day 4 – 6
On the last three days of ESMO 2021, two key presentations highlighting clinical and pre-clinical data for CAR-T candidates treating solid tumors were presented. Additionally, a Controversy Session was held discussing the key benefits and challenges for bispecific antibodies and CAR-Ts.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.